Omeros Corporation Reports Second Quarter 2026 Financial Results

Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2026, which include: ...
diginomica

Did we build the engine before we worked out the physics? What's the pathway to take after the LLM transformer?

Does AI have the cart before the horse? Zuzanna Stamirowska is CEO of Pathway, a company has just been valued at $500 million on the strength of a post-transformer architecture built on first ...

NovelMed Advances NM5072 for Multiple Ocular Disorders

Biogen’s acquisition of Apellis highlights interest in complement-based ophthalmology and multi-indication platforms. NM5072 represents a broad multi-indication opportunity, supported by preclinical ...

NovelMed Advances Its Ocular Program, Highlighting the Potential of a Single Therapy Across Multiple Retinal Diseases

A Versatile Complement Therapy Across Ocular, Hematologic, Renal, Dermatological, and Inflammatory Disorders. Key Highlights Commercial ...
The University of Alabama at Birmingham

Why clinical trials matter: Revolutionary new kidney treatments show what UAB can deliver for Alabama patients

UAB researchers and physician-scientists helped drive a revolution in IgA nephropathy treatment, contributing to clinical ...
News-Medical.Net

Natural hormone activates brain-to-liver signaling pathway to suppress liver inflammation

Researchers at McMaster University have discovered that a naturally occurring hormone best known for suppressing appetite and promoting weight loss also helps protect the liver from inflammation ...